United States: FDA Releases Draft Guidance On Drug And Device Manufacturer Communication Of Health Care Economic Information To Payors, Formulary Committees, And Similar Entities Under FDAMA 114

Last week, the US Food and Drug Administration (FDA) issued a long-awaited draft guidance entitled "Drug and Device Manufacturer Communications with Payors, Formulary Committees and Similar Entities—Questions and Answers"1 (hereafter the "Draft Guidance"). Industry and related stakeholders have been waiting for this guidance since 1997, when Congress first enacted Section 114 of the Food and Drug Administration Modernization Act (FDAMA), which created a safe harbor for proactive manufacturer communication of health care economic information based on competent and reliable evidence, if such information directly related to the FDA-approved indication.

The timing of the Draft Guidance is interesting for three reasons. First, FDA published the Draft Guidance only days before President Trump entered office. FDA had listed FDAMA 114 guidance on its annual agenda for several years. Thus, it is unclear whether publication of the Draft Guidance suggests that FDA was truly finished with its draft or if the agency released it to stake out an agency position before the new administration could alter its content. Second, the publication comes only a few weeks after Congress enacted the 21st Century Cures Act, which made important amendments to FDAMA 114, as described below.

Finally, FDA released the Draft Guidance along with two other very important documents that address product communications by manufacturers: (1) Memorandum: Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products;2 and (2) Medical Product Communications That Are Consistent With the FDA-Required Labeling.3 Outgoing FDA Commissioner Robert Califf issued a press release announcing these new guidance documents, stating that the agency is "committed to an ongoing dialogue with industry and stakeholders" to help "provide clarity ... on FDA's current thinking and recommendations for a few different types of communications about medical products."4 FDA has also opened dockets for public comment on each of the guidance documents.5 These documents come only a few months after FDA held a public meeting on the same topics back in November 2016, and also one week after the agency issued a final rule amending the "intended use" regulation as part of a broader rulemaking focused on the circumstances in which a product made or derived from tobacco will be subject to regulation as a drug, device, or a combination product under the Federal Food, Drug, and Cosmetic Act.6 Collectively, these documents set forth FDA's current positions on the First Amendment as it relates to manufacturer communications. It is possible that the Trump Administration could take different positions when the drafts are finalized. The Draft Guidance on payer communications provides useful insight into FDA's position on the standards and best practices in the creation and dissemination of HCEI.

FDAMA 114: Brief Overview and Recent Amendments

In 1997, Congress enacted Section 114 of FDAMA (21 U.S.C. § 352(a)). As enacted, FDAMA 114 permitted manufacturers to disseminate HCEI to formulary committees (or other similar entities). Under the statute, such communications did not constitute false or misleading promotion if the HCEI: (1) directly related to an FDA-approved indication; and (2) was based on competent and reliable scientific evidence.

In December 2016, Congress amended FDAMA 114 in several significant ways through section 3037 of the 21st Century Cures Act.

  • Revised HCEI Definition: HCEI (as amended by Section 3037) means "any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug." Notably, the amendments specify that such analyses "may be comparative to the use of another drug, to another health care intervention, or to no intervention."
  • Expanded Audience that May Receive HCEI: Manufacturers may disseminate HCEI to payors, formulary committees,7 or other similar entities, with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement.
  • Removal of "Directly": Section 3037 provides that a communication must "relate to" an approved indication of the product and explicitly provides that HCEI that "relates only" to an unapproved indication is not protected. The word "directly" is removed.
  • Applicable Disclaimers: HCEI, where applicable, must include a conspicuous and prominent statement describing any material differences between the HCEI and the labeling of the approved drug.

Accordingly, manufacturers are now permitted to communicate HCEI materials that relate to an approved indication of a product but go beyond that specific labeled indication. Such communications may be to payors, formulary committees, or other similar entities.

FDA Q&A Guidance

The Draft Guidance provides examples and elaboration of the operative terms and conditions of Cures Section 3037.

HCEI

  • FDA clarifies that "HCEI pertains to the economic consequences related to the clinical outcomes of treating a disease (or specific aspect of a disease) or of preventing or diagnosis a disease."
  • FDA also clarifies that "HCEI can be presented in a variety of ways that can include, but are not limited to, an evidence dossier, a reprint of a publication from a peer-reviewed journal, a software package comprising a model with user manual, or a budget-impact model."

Audience That Can Receive HCEI

  • The Draft Guidance proposes that an appropriate audience would include: (1) drug information centers; (2) technology assessment panels; (3) pharmacy benefit managers (PBMs); and (4) "other multidisciplinary entities that review scientific and technology assessments to make drug selection, formulary management, and/or coverage and reimbursement decisions on a population basis for health care organizations." FDA defined "healthcare organizations" to "include entities such as integrated health care delivery networks, hospitals, and hospital systems."
  • FDA asserts that these entities are "constituted to consider HCEI" through a "deliberative process" and should have the appropriate range of "knowledge and expertise in the area of health care economic analysis" "needed to interpret HCEI presented to them to inform their population-based decision-making process." Please note, however, that these proposed standards are derived from the pre-21st Century Cures legislative history, and the plain language of the statute as amended does not in fact require a formal deliberative process, but rather just the requisite expertise and responsibility of the audience for selection of drugs for coverage and reimbursement.
  • FDA states that the Draft Guidance does not apply to dissemination of HCEI to: (1) individual health care providers (HCPs) who are making individual patient prescribing decisions; or (2) consumers (e.g., dissemination via a public web site).

HCEI That "Relates To" an Approved Indication

  • To be considered "related to an approved indication," FDA explains that "HCEI analyses should relate to the disease or condition, manifestation of the disease or condition, or symptoms associated with the disease or condition in the patient population for which the drug is indicated in the FDA-approved labeling."
  • FDA offers 10 examples of HCEI analyses that the agency believes "could be considered related to an approved indication of a drug, despite information that does not appear within, and may vary in certain respects from, information presented in the FDA-approved labeling":

    • Duration of Treatment: HCEI analyses may incorporate information about long-term use of a drug over a period of time that is different from the FDA-approved labeling so long as the approved indication does not limit the duration of use.
    • Practice Setting: HCEI analyses may be based on use of the drug for its approved indication in practice settings that differ from the settings of the clinical trials submitted to FDA in the application (e.g., clinical trials could be extrapolated to a managed care or other setting).
    • Burden of Illness: HCEI analyses may be derived from studies of broad management of a disease for which the drug is indicated, including economic consequences of treatment on clinical outcomes (e.g., economic consequences of absent work days as a result of signs and symptoms associated with a disease).
    • Dosing: HCEI analyses may be based on data or studies of approved dosage forms and strengths of a drug for its approved indication, where the dosing regimen varies from the FDA-approved labeling (e.g., an observational study based on drug utilization data from a health plan database, where actual patient use of an approved dosage form and strength of a drug for an approved indication falls outside the recommended dosing regimen in the label, such as by taking at a different frequency or a different total dose than recommended).
    • Patient Subgroups: HCEI analyses may be derived from analyses of treatment effects in patient subgroups (e.g., demographics, disease severity, co-morbidities) that are within the patient population for the approved indication, even if these subgroup analyses were not pre-specified in the studies that formed the basis for approval of the drug. This is a significant change from FDA's pre-Cures position that such non-pre-specified subgroup analyses were not permitted in proactive promotional HCEI materials.
    • Length of Hospital Stay: HCEI analyses may be derived from studies of treatment impacts on length of hospital stay.
    • Validated Surrogate Endpoints: HCEI analyses may be derived from clinical data demonstrating an effect on a surrogate endpoint that is known to predict clinical benefit (i.e., a validated surrogate endpoint). For example, blood pressure reduction is a validated surrogate endpoint for reduction in certain cardiovascular events (e.g., stroke, myocardial infarction) pertaining to antihypertensive drugs (e.g., calcium channel blockers, angiotensin converting enzyme inhibitors). FDA clarified, however, that if there is "insufficient evidence to demonstrate that a particular surrogate endpoint is capable of predicting clinical benefit, it generally should not be used as a basis for HCEI."
    • Clinical Outcome Assessments (COAs)8 or Other Health Outcome Measures (e.g., Quality Adjusted Life Year (QALY9)): HCEI analyses may be derived from studies involving the approved indication of a drug that assess COAs (e.g., patient-reported outcomes (PROs), such as compliance/adherence, work productivity, basic activities of daily living) or other health outcome measures (e.g., QALY) when they are evaluated using valid and reliable measures (as determined by experts who are familiar with evaluating the merits of a particular COA or other health outcome measure).
    • Persistence10: HCEI analyses may be based on data estimating patient persistence on a drug for its approved indication (e.g., estimates based on drug utilization data from a health plan database).
    • Comparisons: HCEI analyses may be derived from studies comparing the safety or effectiveness of a drug for its approved indication to another drug or intervention or to no treatment. This likely understates the comparative HCEI analyses that can be disseminated under FDAMA 114 as amended. In fact, the revised FDAMA 114 can now be read to permit robust comparative FDAMA 114 analyses – when appropriate qualifying information is provided and competent and reliable evidence exists to support clinical assumptions underlying comparisons – even when an adequate and well-controlled head-to-head trial between the products is not available.
  • Conversely, FDA proposes two examples of HCEI analyses that FDA would not be considered to relate to an approved indication.

    • An economic analysis of disease course modification related to use of a drug that is approved only to treat the symptoms of the disease. FDA offers two examples to illustrate: (1) an analysis of a drug indicated for the acute relief of angina discussing the effect of the drug on delaying the worsening of coronary artery disease (disease course modification); and (2) an analysis of a drug indicated for the treatment of the signs and symptoms of heart failure discussing prolonging patient survival (disease course modification) for patients with heart failure.
    • HCEI analyses derived from studies in patient populations that are not within the indicated patient population. For example, an analysis regarding the treatment of cystic fibrosis (CF) in patients with any mutation in the CF gene would not be considered to relate to the approved indication for a drug approved to treat only one specific CF gene mutation.

Competent and Reliable Scientific Evidence (CARSE)

  • FDA considers HCEI "to be based on CARSE if the HCEI has been developed using generally-accepted scientific standards, appropriate for the information being conveyed, that yield accurate and reliable results."
  • In evaluating HCEI, FDA states that it will consider the merits of existing current good research practices for HCEI substantiation developed by authoritative bodies (e.g., International Society for Pharmacoeconomic and Outcomes Research (ISPOR), Patient-Centered Outcomes Research Institute (PCORI)). For example, "when evaluating HCEI based on indirect treatment comparisons in the absence of data from head-to-head controlled clinical trials, FDA may refer to guidelines issued by external expert bodies regarding current rigorous methodologies and best practices for such comparisons (e.g., network meta-analyses)."
  • FDA also clarifies that it considers the CARSE standard "to apply to all components of HCEI, including inputs and assumptions related to both economic consequences and clinical outcomes (i.e., safety and/or effectiveness)."

Information That Should be Included When Disseminating HCEI

The Draft Guidance proposes that manufacturers should disseminate HCEI with "appropriate background and contextual information necessary to allow payors to fully understand the HCEI," including the following elements, which FDA said should be presented "clearly and prominently."

  • Study Design and Methodology: this includes a statement of the study objectives (e.g., clear description of the hypothesis and potential biases and/or confounders), as well as detailed descriptions and explanations of the following information:

    • Type of Analysis: (e.g., cost-minimization analysis, cost-effective analysis, cost-utility analysis, cost-benefit analysis, cost-consequence analysis) and the reason for its choice.
    • Modeling: an explanation of the model technique chosen, its scope, and its key variables and parameters, as well as the rationale and consequences of including and excluding specific variables in economic models.
    • Patient Population: including the number of patients and relevant demographic information (e.g., age, gender, ethnicity, clinical characteristics, and socioeconomic status).
    • Perspective/Viewpoint: (e.g., patient, employer, health care provider (e.g., clinician, institution), payor, regulatory body (e.g., government agency), or society (i.e., everyone impacted by the treatment)) to enable payors to understand the rationale for the selection of inputs (e.g., outcome measures, time periods, costs), and therefore, determine whether the HCEI is relevant to their particular health care organization.
    • Treatment Comparator (e.g., other drugs, other medical care, no treatment).
    • Time Horizon: including its relation to the major and relevant clinical outcomes (e.g., safety and effectiveness) and economic consequences related to the treatment of interest and its comparators.
    • Outcome Measures: including the sources of clinical and/or nonclinical data (e.g., clinical outcomes could include PROs (i.e., compliance/adherence, work productivity, basic activities of daily living) or QALYs). Data sources could include clinical and nonclinical studies or other sources, such as administrative databases (e.g., health plan databases), electronic health records (EHRs), and registries.
    • Cost Estimates: identifying all relevant resource items for the measurement and valuation of a treatment pathway, including the source of cost data and the date of pricing. Full disclosure of and explanation for any data manipulations and methods (e.g., discount rates, adjustments for inflation, currency conversion) should also be included.
    • Assumptions: including a comprehensive listing of all assumptions (clinical and nonclinical) and associated rationales explicitly in the explanation of the methodology for the economic analysis. Assumptions may include: (1) information related to patient demographics or characteristics; (2) natural disease course; (3) disease management/clinical practice; and (4) cost of clinical events. FDA further recommends that "[a]ll evidence to support assumptions should be provided."
  • Generalizability: The Draft Guidance explains that generalizability "refers to the applicability of HCEI obtained in one health care setting or patient population to another." Accordingly, FDA proposes that firms disclose any "factors which may limit the generalizability of the economic analysis."
  • Limitations: FDA proposes that HCEI include an explicit discussion of the limitations of the economic analysis, including, but not limited to: (1) limitations of the study design;11 (2) limitations of the data sources; (3) incomplete data; (4) assumptions made; (5) choice of comparators; and (6) exclusion of certain clinical outcomes. FDA also proposes that limitations and methodological issues with observational studies and indirect treatment comparisons should be "fully described, as they may inform conclusions that can be reliably made based on these analyses."
  • Sensitivity Analysis: The Draft Guidance proposes that HCEI identify any uncertainties from data sources, extrapolation, or analytic methods that could affect the conclusions in HCEI. FDA also proposes that manufacturers conduct a sensitivity analysis and include adequate disclosures and rationales regarding the method used for the sensitivity analysis, the variables chosen, and the ranges for those variables.
  • Additional Material Information for a Balanced and Complete Presentation: FDA contends that a balanced and complete presentation of HCEI should include the following "material information":

    • A conspicuous and prominent statement describing material differences between the HCEI and the labeling approved for the drug, as required under the statute. FDA also cautions that firms should "not misleadingly represent that clinical assumptions that vary from the FDA-approved labeling have been found by FDA to be safe and effective."
    • FDA-Approved Indication and Labeling.
    • Disclosure of Omitted Studies or Data Sources. The Draft Guidance warns that if "relevant data or information is available but was not considered and included" in the analysis, the HCEI would be considered misleading and incomplete. FDA emphasizes that this would be "especially true if the omitted data or information is from rigorous studies (e.g., adequate and well-controlled trials)."

      • Accordingly, FDA recommends that manufacturers "perform a comprehensive literature search and that their HCEI include an explanation of methods used in the literature search (e.g., databases or sources used, time period covered, and criteria/keywords used to search the databases and sources and to determine what data or information to include/exclude)."
      • "If HCEI is created without using all available relevant data, HCEI should clearly explain that certain studies or data sources were omitted from the analysis, the reasons they were not included, and how such a selective inclusion of studies or data sources may change or affect the conclusions."
    • Risk Information. FDA proposes that HCEI disclose "important risk information" associated with the approved use of the drug and "any additional risk information related to clinical assumptions in economic analyses that vary from the FDA-approved labeling (e.g., risks observed in a particular patient subgroup)."
    • Financial/Affiliation Biases. The Draft Guidance provides that HCEI should disclose potential financial or affiliation biases, including a manufacturer's role in funding the underlying research or in drafting underlying publications or presentations, as well as the names of any authors of studies or analyses who received compensation from the manufacturer or who had a significant financial interest in the firm, "to the extent reasonably known by the firm at the time of dissemination."

HCEI Communications Regarding Investigational Drugs and Devices

  • The Draft Guidance clarifies that FDA does not intend to object, under 21 C.F.R. §§ 312.7(a) or 812.7(a) or otherwise, to HCEI communications to payors prior to FDA approval or clearance when such communications are "unbiased, factual, accurate, and non-misleading." Examples of acceptable information that can be conveyed to payors include:

    • product information (e.g., drug class, device design);
    • information about the indication sought, such as information from the clinical study protocol(s) about endpoint(s) being studied and the patient population under investigation (e.g., number of subjects enrolled, subject enrollment criteria, subject demographics);
    • factual presentations of results from clinical or preclinical studies (i.e., no characterizations or conclusions should be made regarding the safety or effectiveness of the product);
    • anticipated timeline for possible FDA approval/clearance;
    • product pricing information; and
    • targeting/marketing strategies (e.g., outreach activities planned to generate prescriber awareness about the product) product-related programs or services (e.g., patient support programs).
  • FDA proposes that HCEI regarding investigational drugs and devices should include:

    • a clear statement that the product is under investigation and that the safety or effectiveness of the product has not been established; and
    • information related to the stage of product development (e.g., the phase of clinical trial in which a product is being studied and how it relates to the overall product development plan).
  • FDA also suggests that manufacturers "provide follow-up information to payors if previously communicated information becomes outdated as a result of significant changes or as a result of new information regarding the product (e.g., failure to meet primary effectiveness endpoint in the phase 3 trial) or its review status (e.g., an application is determined to not be ready for approval upon completion of the review cycle, a study is placed on a clinical hold)."
  • FDA asserts – consistent with its prior position on pre-approval promotion – that it would be inappropriate for a manufacturer to represent in communications that an investigational product is FDA-approved/cleared or is otherwise safe or effective for the purpose(s) for which it is under investigation.

HCEI Regarding Unapproved Uses of Approved Drugs

  • FDA states that communications of HCEI regarding unapproved uses of approved drugs are subject to three existing draft guidance documents: (1) Responding to Unsolicited Requests for Off-Label Information; (2) Good Reprint Practices; and (3) Distributing Scientific and Medical Publications.
  • FDA notes that manufacturers can disseminate HCEI regarding unapproved uses to payors consistent with the recommendations outlined in these three guidance documents. The Draft Guidance, however, did not provide any further insight or detail in this area, or address the First Amendment questions surrounding FDA's prior policies with respect to truthful and non-misleading information regarding unapproved uses of approved drugs.

HCEI and Contracting Discussions

  • FDA recognizes that communication of HCEI occurs during the course of discussions with payors related to risk-sharing and other value-based contracts. FDA confirms, however, that the Draft Guidance "is not intended to address the terms of contracts between firms and payors" as FDA does not regulate such contracts.

Post-Marketing Requirements

  • The Draft Guidance clarifies that HCEI disseminated in accordance with section 502(a) of the FDCA "is promotion, and, therefore, is subject to FDA's requirements for submission of promotional materials" at the time of initial publication or dissemination (using Form FDA 2253)(citing 21 C.F.R. § 314.81(b)(3)(i)). HCEI about drugs approved under the accelerated approval pathway or drugs based on animal studies must comply with the pre-dissemination submission of promotional materials.
  • FDA explains that all supporting information for HCEI should be "referenced" in the postmarketing submission.
  • FDAMA 114 permits FDA to request submission of information that is relevant to the substantiation of HCEI, which FDA states may "include the primary data and analysis methods used to support the HCEI."

Enforcement

  • FDA confirms that, for manufacturers that disseminate HCEI consistent with the Draft Guidance, the agency does not intend to consider such information false or misleading.
  • FDA further announces that the agency does not intend to cite dissemination of compliant HCEI as evidence of a new intended use.

Analysis and Impact of FDA's Draft Guidance

The Draft Guidance contains a significant amount of technical recommendations and considerations for manufacturers and related stakeholders regarding the creation, dissemination, and use of HCEI. While a number of the recommendations are consistent with longstanding industry practice, FDA's first official document addressing FDAMA 114 (as amended by the 21st Century Cures Act) now memorializes a number of important concepts and principles that companies will need to consider moving forward.

First, manufacturers should assess whether current practices for generating and substantiating HCEI are consistent with authoritative health care economic research bodies and are otherwise robust enough to meet the CARSE standard. In doing so, companies should update policies and procedures with the amended statutory definition of HCEI, as well as clarify the acceptable formats for which HCEI may be presented in (e.g., peer-reviewed journals, economic software models, etc.).

Second, manufacturers should consider documenting when and how the payor, formulary committee, or other similar entity audience for proactive HCEI has the requisite knowledge and expertise in the area of health care economic analysis and is carrying out its responsibilities for the selection of drugs for coverage or reimbursement.

Third, manufacturers should update HCEI research practices to ensure that studies are designed and modeled in a manner that will "relate to" a drug's FDA-approved indication. In particular, companies may want to create a checklist of the various examples used by FDA, and identify any other potentially acceptable study designs.

Fourth, companies should ensure that all components of HCEI, including inputs and assumptions related to both economic consequences and clinical outcomes, meet the CARSE standard, as clarified by FDA in the Draft Guidance. This standard will be particularly important to consider to ensure compliance when HCEI is comparative in nature and there is no underlying head-to-head clinical studies between the products addressed in the HCEI.

Fifth, manufacturers should assess whether current processes and procedures address the types of information that FDA expects to be disseminated along with HCEI (e.g., study design and methodology, limitations, sensitivity analysis, etc.). Companies should update promotional review processes (e.g., updated forms, checklists, or software) to ensure that all required information is compiled and submitted along with HCEI to allow for robust review and discussion to ensure compliance with the Draft Guidance. Particular attention to these details will be helpful given FDA's expectation that manufacturers include discussions about study limitations, incomplete data, assumptions, and omitted studies or data sources, as well as FDA's statutory authority to request data used to substantiate HCEI. Companies should also update promotional review processes, systems, and procedures to ensure that all "material information" outlined by FDA is included in HCEI packages (e.g., conspicuous statement, FDA labeling, conflicts of interest, and risk information), and postmarketing submission to FDA is addressed.

Sixth, companies should account for the different standards FDA outlined for the dissemination of HCEI regarding investigational products. Importantly, manufacturers should identify systems that will remind applicable personnel of when "follow-up information" may be required.

Finally, manufacturers should consider whether developing First Amendment case law may permit the proactive dissemination of robust, truthful, and non-misleading HCEI beyond the strict terms of FDA's interpretation of FDAMA 114.

Comments on this guidance are due by April 19, 2017 (Docket No. FDA-2016-2-1307).

Footnotes

1. FDA, Draft Guidance, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers (January 2017).

2. FDA, Memorandum, Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (January 2017).

3. FDA, Draft Guidance, Medical Product Communications That Are Consistent With the FDA-Required Labeling – Questions and Answers (January 2017).

4. FDA Statement, Statement from FDA Commissioner Robert Califf, M.D. (January 18, 2017).

5. Draft FDAMA 114 Guidance (Docket No. FDA-2016-D-1307); First Amendment Memorandum (Docket No. FDA-2016-N-1149); and Consistent With Label Draft Guidance (Docket No. FDA-2016-D-2285).

6. See 82 Fed. Reg. 2193 (Jan. 9, 2017).

7. FDA clarified in the Draft Guidance that formulary committees "refer{ } to multidisciplinary committees that have the responsibility for selection of drugs and the management of a drug formulary," and uses the example of pharmacy and therapeutic committees.

8. FDA defined COA to mean "any assessment of a patient's clinical state by the patient or a clinician," and noted that there are four types of COA measures (i.e., patient-reported outcomes, clinician-reported outcomes, observer-reported outcomes, and performance outcomes).

9. FDA defined QALY to mean "a measure of the value of a health outcome that is typically scored on a scale from zero (corresponds to death) to one (corresponds to perfect or optimal health), integrating the life expectancy and treatment impact on morbidity of the compared interventions that may be used in HCEI."

10. FDA explained that persistence refers to "the duration of time from initiation to discontinuation of therapy" (citation omitted).

11. Regarding study design limitations, FDA maintained that firms should disclose whether the study: (1) lacked randomization, blinding, or a control group; (2) lacked assay sensitivity; (3) failed to include pre-specified endpoints; (4) failed to include endpoints that are valid and reliable measures of the outcomes of interest; (5) failed to identify dosing, patient population, patient drop outs, selection and timing of endpoints; and (6) failed to meet the primary endpoint.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions